Answers are grounded in this paper and cite their sources.
17 β -estradiol can effectively slow down progression of myocardial infarction (MI), and is expected to have more curative effects. Therefore, this study investigated the mechanism underlying cardioprotective role of 17 β -estradiol NPs in rats with MI. After construction of rat MI model and preparation of 17 β -estradiol NPs, the rats were administered with 17 β -estradiol alone, 17 β -estradiol NPs and Akt agonist or inhibitor. Distribution of 17 β -estradiol NPs was observed by fluorescence microscope and release curve was detected. After treatment, echocardiography was conducted to measure the cardiac function indicators. With HE staining to observe myocardial tissue, RT-qPCR and Western blot determined levels of AKT and eNOS. The NPs were relatively uniform in size and round in shape; and cumulative release rate and concentration of 17 β -estradiol in rats reached highest level on 30th day. Treatment with 17 β -estradiol or 17 β -estradiol NPs importantly increased survival rate of MI rats and decreased MI area while improving LVSP, LVDP, and HR. Moreover, the 17 β -estradiol NPs had the smallest MI area. The myocardial tissue of rats in the 17 β -estradiol NP group was closely arranged, and myocardial collagen was significantly reduced. The 17 β -estradiol NPs increased the mRNA level of eNOS and Akt when eNOS expression was related to Akt expression. 17 β -estradiol NPs can therefore increase the expression of eNOS by activating Akt signaling pathway, thereby relieving the myocardial injury in rats, hindering progression of MI.
No takes yet. Share an insight, caveat, or question.
Zuo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: